0001209191-21-003168.txt : 20210111
0001209191-21-003168.hdr.sgml : 20210111
20210111211816
ACCESSION NUMBER: 0001209191-21-003168
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210107
FILED AS OF DATE: 20210111
DATE AS OF CHANGE: 20210111
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aurentz Vincent
CENTRAL INDEX KEY: 0001657494
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-31161
FILM NUMBER: 21522235
BUSINESS ADDRESS:
STREET 1: C/O ARENA PHARMACEUTICALS, INC.
STREET 2: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (858) 453-7200
MAIL ADDRESS:
STREET 1: C/O ARENA PHARMACEUTICALS, INC.
STREET 2: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER NAME:
FORMER CONFORMED NAME: Vincent Aurentz
DATE OF NAME CHANGE: 20151103
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001080709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 232908305
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-453-7200
MAIL ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-07
0
0001080709
ARENA PHARMACEUTICALS INC
ARNA
0001657494
Aurentz Vincent
C/O ARENA PHARMACEUTICALS, INC.
6154 NANCY RIDGE DRIVE
SAN DIEGO
CA
92121
0
1
0
0
Executive VP and CBO
Common Stock
2021-01-07
4
M
0
18000
0.00
A
27000
D
Performance Restricted Stock Unit
2021-01-07
4
M
0
18000
0.00
D
2022-01-03
Common Stock
18000
0
D
On January 4, 2019, the Reporting Person was granted 12,600 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq "Closing Price" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. 6,300 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount), and another 6,300 of the shares subject to the PRSUs (50% of the target amount) vested in Nov. 2020. The final 12,600 shares issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) vested and released on January 7, 2021, as reported herein.
The amount reported in Column 7 of Table II represents the common shares that vested on January 7, 2021. The PRSUs have now fully vested and no common shares remain issuable thereunder.
/s/ Andrew J. Cronauer, as Attorney-in-Fact
2021-01-11